I wouldn't bet on that Hofno2003 ; you are dead wrong, Takeda too had everything which you claim for Sanofi. Good luck on that.........what applied to Sanofi applied to Takeda too...
so POZN is another SCMP
U.S. drugmaker Sucampo Pharmaceuticals is seeking talks with marketing partner Takeda Pharmaceutical Co Ltd to mend their relationship, after losing a two-year legal battle to sever ties with the Japanese company.
The International Court of Arbitration ruled against Sucampo on Friday in a dispute resulting from the biotechnology company's dissatisfaction with Takeda's marketing of its constipation drug, Amitiza.
The company, which had sought damages and wanted to dissolve its tie-up with Takeda, depends on Amitiza for most of its revenue, derived from royalties paid by Takeda.
Sucampo, which signed the deal with Takeda in 2004, began arbitration in 2010, alleging that its Japanese partner's meek marketing of Amitiza had failed to drive satisfactory sales.
dead money because the partner not really interested in marketing as POZN wanted. Which means lower royalties and in the case POZN partner already has enough enough.... so why would they go for aggressive marketing.. if it sells well and good ... if it doesn't who really cares..
So all the excitement about POZN hitting $20 is premature
you forgot to mention the ultra orphan status for
1) Rindopepimut ( CDX-110 ) is a cancer drug that received orphan drug status in the U.S. and Europe in addition to Fast Track status in the U.S.
2) CDX-1135 DDD is ultra-orphan indication too which means potential for breakthrough status.
Sales and Pricing......hmmmm... between $250K to $300K ?
any approx time frame
CLDX close will be around $24, going up look at RSI, here we go fasten your seat belts
don't tell me CITRON is writing on GALE. what could they possibly write after so much has been already posted !!!!!!!!!!!!!!!!!!!!!
or early morning tomorrow....... GLTA......
Sentiment: Strong Buy
yes, not really hard to get 10,000 blind people first year
it will have to be covered by insurance. i am not sure about medicaid and medicare...someone else could answer that
Sentiment: Strong Buy
looks like momentum money going there in NKTR
will it touch
thanks for your leads, you mentioned GALE back in Dec 18
We just bought 359,000 shares at $3.90 , remaining 41,000 shares to be purchased at $4.40
Our price target for GALE $9 FY2014
Cohen Investment Group
I purchased GALE at $3.95 and sold at $5.45
Now I will buy PGNX